• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Pfizer (NY:PFE)

    27.31 -0.21 (-0.76%)
    Official Closing Price Updated: 7:00 PM EDT, Apr 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Pfizer

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    News headline image
    Why Merck (MRK) Shares Are Trading Lower Today
    What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
    Via StockStory
    Topics Government Intellectual Property
    News headline image
    A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
    There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
    Via The Motley Fool
    News headline image
    This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
    Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock. 
    Via The Motley Fool
    Topics Intellectual Property Stocks
    News headline image
    Where Will Pfizer Stock Be in 3 Years? ↗
    The healthcare giant has been investing heavily in its future growth. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
    One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    2 Value Stocks to Research Further and 1 Facing Headwinds
    Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
    Via StockStory
    News headline image
    QSM Asset Management Loads Up 611,000 Mobileye Shares ↗
    Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers. 
    Via The Motley Fool
    Topics Economy Regulatory Compliance Supply Chain
    News headline image
    A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗
    Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    What to Look for Before Buying a Pharma Stock ↗
    Start with the drug pipeline when researching pharma stocks to own. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗
    ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
    Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
    Via MarketMinute
    Topics Economy Intellectual Property
    News headline image
    MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
    In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
    Via MarketMinute
    Topics Bankruptcy Earnings Economy
    News headline image
    Earnings Preview: What to Expect From Pfizer’s Report
    Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range. 
    Via Barchart.com
    News headline image
    Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends ↗
    These stocks have been struggling in recent years, but they are safer investments than they appear to be at first glance. 
    Via The Motley Fool
    Topics World Trade
    News headline image
    The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
    As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,... 
    Via Finterra
    Topics Artificial Intelligence Death Economy
    News headline image
    Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
    Via PRLog
    News headline image
    Better Buy Right Now: Johnson & Johnson Vs. Pfizer ↗
    The choice is based on more than just the dividend payout. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe? ↗
    The company has increased its payouts over the past five years despite significant challenges. 
    Via The Motley Fool
    News headline image
    Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
    In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total... 
    Via MarketMinute
    Topics Bonds
    News headline image
    Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
    As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    Telix Strengthens Board with Additional Director Appointments
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    News headline image
    The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
    In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the... 
    Via MarketMinute
    News headline image
    OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
    Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma... 
    Via Newsfile
    News headline image
    Why Pfizer Stock Tumbled on Tuesday ↗
    One analyst reiterated his pessimistic view of the pharmaceutical titan's future. 
    Via The Motley Fool
    Topics Intellectual Property
    Curious about the most active S&P500 stocks in today's session? ↗
    Via Chartmill
    News headline image
    Why Is Pfizer Stock Dropping Tuesday? ↗
    Pfizer Inc (NYSE:PFE) shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot trial. 
    Via Benzinga
    News headline image
    Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today ↗
    The healthcare stock looks ridiculously undervalued. 
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
    From AINewsWire
    Via GlobeNewswire
    News headline image
    Covered Call Screener Results for April 7th
    Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase. 
    Via Barchart.com
    News headline image
    Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
    On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total... 
    Via MarketMinute
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    99 100 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.